Seoul National University

Kangwon National University Industry Cooperation Foundation

Catholic University Industry Academic Cooperation Foundation

Min Jueng Kang

Eugene C Yi

Donghyun Kim

Dongjin Jeong

Joo Youn Lee

Yeong Wook Song

Doo Hyun Chung

Kristine M Kim

Eunhee G Kim

Wan-Uk Kim

Daehee Hwang

Yune Jung Park

Sung Youg You

The present invention relates to a composition for preventing or treating diseases caused by overexpression of chemokine CXCL1 (fractalkine) comprising a death receptor 5 (DR5) inhibitor as an active ingredient, a method for preventing or treating diseases caused by overexpression of chemokine CXCL1 comprising administering a DR5 expression or activity inhibitor to a patient in need of prevention or treatment of diseases caused by overexpression of chemokine CXCL1 in a therapeutically effective amount, and a use for prevention or treatment of diseases caused by overexpression of chemokine CXCL1 of a DR5 expression or activity inhibitor.

Composition for preventing or treating diseases caused by overexpression of chemokine CXCL1, containing death receptor inhibitor as active ingredient

A peptide for treating rheumatoid arthritis and use thereof are provided, and a peptide consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 or a polynucleotide encoding the same, and a pharmaceutical composition for treating rheumatoid arthritis or a health functional food composition for improving rheumatoid arthritis, each including the peptide, are provided.

Peptide for treating rheumatoid arthritis and use thereof

The present disclosure relates to a method for producing a monoclonal antibody that binds to an epitope for the glycan binding site of a glycoprotein. According to the present disclosure, a monoclonal antibody that recognizes the glycan binding site of a glycoprotein as an epitope can be produced in a relatively simple and economic manner, and a monoclonal antibody having high sensitivity and specificity for the glycan binding site of a glycoprotein can be produced. The monoclonal antibody produced according to the present disclosure can be effectively used as an agent for diagnosing or treating various diseases associated with a change in glycan structure or glycan expression level.

Methods for preparing monoclonal antibodies recognizing glycan binding site as an epitope

Growing community of inventors

Seoul, South Korea

Min Jueng Kang